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Abstract
Asthma is a multifactorial and complex disease, with different degrees of risks and 
severity, as well as the response to treatment. Medications currently available are most 
effective in severe asthma; nonetheless, there is a percentage of patients that have no 
response to the treatment that guidelines suggest in their recommendations. In the last 
years, there have been new insights in inflammatory molecules that contribute to asthma 
physiopathology and a lot of them have been considered to be possible targets in the 
management of severe asthma. As a consequence of this, a few monoclonal antibodies 
have been developed evidencing their effectiveness in the treatment of the disease. The 
study of these new therapies has allowed the identification of specific inflammatory path-
ways. This chapter intends to offer a critical perspective of the current guidelines for the 
management of severe asthma, as well as to discuss current treatments and the future 
on new molecules. Through an adequate characterization, different phenotypes will be 
recognized and associated with a determinate biomarker and should be used to select the 
treatment that can offer the highest efficiency in these patients. In this way, the treatment 
will be directed to a personalized medicine.
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1. Introduction
Asthma is a heterogeneous disease characterized by chronic airway inflammation. The GINA 
guidelines indicate that inflammation control is a key for management goals and as such is 
considered a treatment priority. Severe asthma represents a good part of the health spend-
ing, with significant impact on patients’ quality of life. Hence, the identification and cor-
rect treatment of severe asthma may help to control exacerbations and the inflammatory 
process, thus improving the personal, social, and economic impact of the disease [1]. In the 
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pathophysiology of asthma, there are multiple processes mediated by various cytokines and 
cells that cause inflammation. Management goals have been directed toward these molecules 
and cell targets through the use of corticosteroids, which have meant a dramatic change in 
the control of the disease. However, these drugs act in a nonspecific way. Furthermore, the 
development of new monoclonal antibodies could represent a significant milestone for treat-
ment of asthma, reinforcing the essential idea of personalized medicine. In 1984, researchers 
Jerne, Köhler, and Milstein received the Nobel Prize in Medicine for their work on plasma 
cell and multiple myeloma cell fusion, which allowed the generation of specific antibodies 
with the appropriate genetic information, but at high speed. In subsequent years, immuno-
globulins synthesized from this new technology, with specific target molecules, such as the 
endotoxin of Gram-negative bacteria in sepsis, demonstrated an initial benefit. Subsequently, 
the concept of personalized medicine began to take shape, and in recent years, biomedical 
research has focused on deepening the molecular mechanisms underlying various patholo-
gies, parallel to the production of new drugs that act at crucial points of specific immu-
nological cascades. Therefore, monoclonal antibodies are an effective and safe therapeutic 
alternative in many chronic diseases such as rheumatoid arthritis, cancer, and asthma and 
are seen as a hopeful option in many other diseases. The challenge now is not to get lost in 
the wide variety of clinical studies that can be found in the literature, as well as in connecting 
a particular patient with the appropriate management based on the evidence.
2. Critical view of current guidelines and treatment
Large studies on severe asthma have expanded our knowledge about the characteristics of the 
disease. Severity is defined as the requirement for systemic corticosteroids more than twice a year, 
the need for at least one hospitalization, previous admission to an intensive care unit, the need 
for mechanical ventilation in the previous year, impaired pulmonary function determined by a 
forced expiratory volume in the first second (FEV1) less than 80% of the predicted in the presence 
of forced vital capacity (FVC) below normal limits after the administration of bronchodilator, or 
the use of high doses of corticosteroids inhaled and long-acting beta-2-agonists without achiev-
ing control of symptoms [2]. In fact, it is estimated that 50% of patients are not well-controlled 
despite receiving optimal treatment, and that 5–10% do not respond to treatment. Also, receiv-
ing high doses of inhaled or systemic corticosteroids increases the risk for adverse effects, which 
implies an affectation of the additional quality of life due to the sum of other secondary diseases 
[3]. The GINA guidelines include evidence-based diagnostic and therapeutic recommendation 
derived from studies that meet all criteria of scientific validity. However, it is possible that in 
selected patients, guidelines do not accurately reflect what a clinician is trying to address.
The guidelines suggest management according to severity and control, symptom dynam-
ics and pulmonary function, but these are directed to the total population of patients with 
asthma [1]. In this sense, there will always be a percentage of patients who either receive a 
suboptimal treatment or who remain unresponsive despite being in the most serious step. 
Finally, the guidelines are not based on the characteristics of the specific inflammation related 
to the different phenotypes, which are the ones that could define with greater precision what 
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would be the ideal treatment to stop a specific pathophysiological mechanism [4]. It is not suf-
ficient then to establish a management based only on severity, since there are several aspects 
that arise from the very concept that asthma is a heterogeneous disease and with different 
molecular and genetic bases, so if a patient should be typecast within a general parameter, 
reduce their therapeutic options [5]. On the other hand, the control of severe asthma repre-
sents a challenge for specialists in allergology and pneumology due to the high impact of this 
disease on the quality of life of patients. The GINA guidelines establish levels of disease con-
trol according to the response to treatment as follows: well-controlled, partially controlled, 
and uncontrolled. However, it can differ as patients cataloged in one of the degrees, in reality 
corresponding to another, taking into account that probably a partially controlled asthma is 
actually an uncontrolled asthma and that this has therapeutic implications. In daily practice, 
middle terms cannot be established to define management. Some patients persist without 
control despite established therapeutic recommendations, which allows us to infer that as 
with severity, there are other aspects that should be evaluated from the pathophysiology of 
the disease and not only based on the degree of control of the disease. Additionally, the clas-
sification based on control is very strict and poorly documented.
2.1. Approach by phenotypes
It is clear that some characteristics can be identified in some asthmatic patients and not in 
others; from this arises the concept of “phenotype,” which is defined as the presence of dif-
ferent characteristics that are the product of the interaction of genes with the environment. 
There may be overlap between them and that the same patient can migrate transiently or 
definitively from one phenotype to another. The challenge, therefore, is to determine in each 
patient the individual characteristics.
Several years ago, Chung and Adcock [6] published a review about phenotyping of asthma. 
The first systematic study of severe asthma carried out in Europe by the group ENFUMOSA 
(European Network for Understanding Mechanisms of Severe Asthma) [7] consolidated the con-
cept that asthma has a heterogeneous expression, and thus, severe asthma should be considered 
a different form of the disease, more than simply an increase in the symptoms of it. Subsequent 
studies included in the Severe Asthma Research Program (SARP) of the United States, together 
with the results of the ENFUMOSA group, and subsequently of the BIOAIR (Longitudinal 
Assessment of Clinical Course and BIOmarkers in severe chronic AIRway Disease) [8], have 
extended the knowledge of clinical expressions and generated new hypotheses about the patho-
physiology of severe asthma. In this way, five phenotypes have been established:
1. Early onset atopic asthma with airway dysfunction, eosinophilic inflammation, and high 
number of hospitalizations.
2. Asthma with noneosinophilic inflammation, obesity, and present in the female sex.
3. Early onset asthma, with few symptoms and minimal eosinophilic inflammation.
4. Asthma with eosinophilic inflammation, with few symptoms and delayed onset.
5. Asthma with neutrophilic inflammation.
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2.1.1. Severe asthma early onset
It comprises 40% of all severe asthmatics. Patients develop the disease in childhood and have 
a history of atopy, increased bronchial hyperresponsiveness, higher levels of total immuno-
globulin E (IgE), and a higher eosinophil count both peripherally and in sputum, as well as a 
tendency to subendothelial fibrosis and overexpression of the mucin gene. In general terms, 
they respond to management with inhaled corticosteroids. Family history suggests a genetic 
component; in fact, multiple studies have reported associations between genes related to the 
expression of the Th2 phenotype and multiple polymorphisms related to greater severity. 
The Th2 pattern of cytokines, including interleukins (IL) 2, 4, 5, 9, and 13, is expressed in the 
bronchial submucosa of these patients. These cytokines contribute to the allergic inflamma-
tion of the airway, generating the activation and the recruitment of B lymphocytes producing 
specific IgE, mast cells, basophils, and eosinophils. IL-13 also acts as an inducer of the genes of 
regulator 1 of the chlorine channels, periostin, and the inhibitor of serpin peptidase.
Recently, the role of thymic stromal lymphopoietin (TSLP) has been described as an inducer 
of IL-4, -5, and -13 production in the initiation of cellular response mediated by Th2 pattern 
cells, as well as IL-25 and -33, which are produced in response to exposure to allergens, con-
taminants, and viruses. IL-33, which is a member of the cytokine family of IL-1, possesses 
potent induction and chemotactic activity of Th2 lymphocytes. Elevated levels of IL-33 and 
TSLP have been observed in patients with asthma, especially in severe cases [9].
2.1.2. Phenotypes with and without eosinophilia
An increased presence of eosinophils in induced sputum and in peripheral blood can iden-
tify the eosinophilic subgroup. The cutoff points are at least 3% of eosinophils in the sputum 
and peripheral eosinophilia greater than 350 (absolute number). The noneosinophilic phe-
notype has been defined as asthma with eosinophils in induced sputum less than 3% and 
increased neutrophilic infiltration. The mechanisms that explain neutrophilia in the airway 
are not very clear. It has been suggested that this phenotype reflects a “non-Th2” pattern with 
all its molecular implications. In addition, it is associated with a poor response to treatment 
with inhaled corticosteroids (even inducing even more neutrophilia), suggesting a Th1 pat-
tern orchestrated by the tumor necrosis factor alpha (TNFɑ), which is assumed to have an 
important role. Both Th17 cells and bacterial colonization of the airway secondary to defects 
in phagocytosis have been implicated as causes of neutrophilia [10].
The identification of phenotypes results in a large number of treatments with specific objec-
tives, which have been developed for some years. The challenge is to unify the physiopa-
thology with clinical phenotypes and use that knowledge to discover other phenotypes 
that have not yet been recognized. None of the clinical phenotypes established to date has 
a detailed identification of their pathophysiology, biomarkers, genetic elements, stability 
over time, or the response to a specific treatment. Probably, all the factors that influence a 
phenotype will need to be incorporated into an endotype, which is nothing else than the 
subtype defined by the functional or pathophysiological mechanism of the disease for a 
particular individual.
The support of the evidence regarding the conformation of phenotypes and endotypes con-
tinues to be limited by the lack of large-scale longitudinal studies that may intertwine the 
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pathophysiology with the clinical findings. However, there are already phenotypes that seem 
to be clearly defined in terms of their clinical and molecular bases, and in which the pharma-
cological intervention with monoclonal antibodies constitutes an important starting point in 
the management of severe asthma [2].
3. Monoclonal antibodies
Monoclonal antibodies are specialized glycoproteins produced by B cells from a stem cell, 
forming identical clones of it. They can recognize specific molecules, such as cytokines or 
receptors.
3.1. Chimeric monoclonal antibodies
They are artificial molecules in which the constant portions of the heavy and light chains come 
from a human immunoglobulin and the variable regions VL and VH (variable region of the 
light and heavy chain, respectively) are obtained from an antibody of murine origin. The goal 
with the construction of a chimeric antibody is to reduce immunogenicity without affecting 
the selectivity of the antibody for the antigen. These molecules have 66% of human compo-
nent and 33% of murine origin; they are less immunogenic than the first-generation monoclo-
nal antibodies, but they can still induce an immune response against them. Antibodies of this 
type end with the prefix ximab (e.g. infliximab, rituximab).
3.2. Humanized antibodies
These molecules have 90% of human origin, so when it is injected into the patients, there is 
no response from the immune system. Only the antigen binding site (paratope) is of murine 
origin and is formed from the spatial combination of the hypervariable loops. The rest of the 
variable region (called M) only works as a scaffold whose function is to serve as structural 
support to the paratope. In this way, the epitopes associated with the murine M regions, 
which are present in the chimeric antibodies, are not found in the humanized antibodies. This 
type of antibody ends with the prefix zumab (e.g., omalizumab, trastuzumab).
3.3. Human antibodies
Almost 100% of its structure is human. However, while the production of mouse monoclonal 
antibodies is routinely carried out by hybridoma technology, the production of human mono-
clonal antibodies by this technology has been difficult, because the human hybridomas and cell 
lines derived from multiple myeloma have been difficult to develop and immunization in vivo is 
not feasible for many antigens. However, several techniques make it possible to generate human 
monoclonal antibodies, such as the expression of immunoglobulin fragments, the single-chain 
variable fractions, and the single strands of the variable fraction. Currently, the development 
of recombinant monoclonal antibodies by phage library technology with genes that encode the 
immunoglobulin variable regions has proven useful in basic and clinical research. This type of 
antibody ends with the prefix mumab or numab (e.g. adalimumab, secukinumab) [11–13].
The traditional production process of monoclonal antibodies is outlined in Figure 1.
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3.4. Development and production
The production of monoclonal antibodies is based on the method of fusion of B lymphocytes 
from an immunized animal (usually a mouse), with an immortal myeloma cell line and the cul-
ture of the cells in a medium in which the nonfused normal and tumoral cells cannot survive. 
The resulting fused cells that are obtained are called hybridomas and each hybridoma produces 
only one immunoglobulin, derived from a B lymphocyte of the immunized animal [11]. The 
method as such consists of the fusion of spleen cells from a mouse immunized to an antigen or 
mixture of known antigens, with a myeloma cell line, with the subsequent formation of hybrid 
cells that preserve many chromosomes of the fused pairs. These cells are then placed in a selec-
tion medium that allows the survival only of immortalized hybrids, which in turn are cultured 
as cell clones that secrete the antibody of interest. This method of selection includes hypotaxine, 
Figure 2. Schematic process for the production of monoclonal antibodies. Xp: “X” protein.
Figure 1. Types of monoclonal antibodies according to their humanization.
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aminopterin, and thymidine, and is therefore called HAT [14]. Antibody-producing hybrid-
omas are expanded in larger capacity culture vessels, and the cells are harvested by centrifuga-
tion, suspended in culture medium supplemented with fetal calf serum and dimethyl sulfoxide 
(DMSO) to freeze, first at −70°C and then in liquid nitrogen. The production of the monoclonal 
antibody is made from the supernatant of bulk cultures or after intraperitoneal inoculation of 
the hybridoma in histocompatible animals. In the latter case, an antibody-producing tumor is 
produced that generates an ascitic fluid rich in these. In both cases, the monoclonal antibodies 
are separated and purified by conventional methods [15] (Figure 2).
4. Current and future targets in the management of asthma
4.1. Current targets
4.1.1. Nonspecific blockade of inflammation (corticosteroids and leukotriene antagonists)
At present, asthma control focuses on the use of inhaled corticosteroids, either alone or in 
association with leukotriene antagonists, and/or long-acting beta-2 agonists. Numerous 
studies have documented the efficacy of corticosteroids in reducing inflammation, both in 
children and adults and at any degree of severity. Currently, they are considered the most 
effective drugs to achieve control in most cases. Its action requires binding to a cytoplasmic 
receptor (alpha GR), which is associated with heat shock proteins (Hsp90-Hsp60). The bind-
ing of the corticoid to its receptor induces the dissociation of these proteins and the transloca-
tion of the complex toward the nucleus where several events occur that lead to the activation 
of the transcription of anti-inflammatory genes and the blocking of those pro-inflammatory. 
Additionally, corticosteroids interact directly with transcription factors, such as the nuclear 
factor kB, further blocking the expansion of the inflammatory process.
The use of these drugs has made it possible to reduce both the symptoms and the frequency 
and severity of the exacerbations, improving quality of life, lung function, and reducing bron-
chial hyperreactivity. However, their lack of specificity makes them susceptible to generating 
adverse effects in different organs. In addition, there is a percentage of patients resistant to 
corticosteroids, a phenomenon explained, among other causes, by the presence of a receptor 
isoform unable to bind to the glucocorticoid [16].
It is difficult to know if in the medium or long term, corticosteroids will continue to be the 
standard asthma therapy. Likewise, it is uncertain whether the advent of monoclonal anti-
bodies will allow the reduction of the dose of corticosteroids and/or their total clearance in 
patients with severe asthma. The cysteinyl leukotrienes comprise C4, D4, and E4 leukot-
rienes. They are mediators that play an important role in inflammation, mucus secretion, 
bronchospasm, and remodeling. The antagonists of the type 1 receptors of cysteinyl leukot-
rienes (montelukast) are potent and selective and block their action in a competitive manner, 
generating an interruption of the pro-inflammatory intracellular cascade with a subsequent 
reduction of its effects. Clinical studies show that antagonism of these receptors is beneficial 
to some degree and percentage of the population. However, it is never superior to the effects 
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achieved with corticosteroids used as monotherapy or in combination with long-acting beta-2 
agonists. The precise indications for use in asthma have not been completely defined. It seems 
that its administration in transient early wheeze triggered by virus and without atopy works 
to a certain extent [17].
4.1.2. Long-acting β-agonists (LABA) combined
The agonist stimulation of the beta 2 adrenergic receptors generates smooth muscle relaxation 
of the central and peripheral airways, reversing the bronchial obstruction in asthmatics. The 
effect is given by the activation of adenylate cyclase (it catalyzes the conversion of adenosine tri-
phosphate—ATP—into cyclic adenosine monophosphate—AMPc), generating the decrease in 
intracellular calcium, and thus causing muscle relaxation. This treatment always associated with 
a corticoid is a choice when control is not achieved with the inhaled corticosteroid alone [18].
4.1.3. Anti-IgE therapy
IgE is a clear therapeutic goal in allergic diseases. It is released by the plasmocyte, binds to its 
receptor of high affinity in the mast cell, and later, upon exposure to the allergen involved, 
induces several effector responses including the release of mediators responsible of allergic reac-
tion. Omalizumab, a recombinant humanized monoclonal antibody, binds specifically to free 
serum IgE in its CH3 domain, near the high-affinity receptor binding site, thereby blocking its 
interaction with mast cells, basophils, antigen-presenting cells, and other inflammatory cells that 
express the receptor. That binding results in the decrease of free IgE, generating a negative feed-
back of the receptor of high affinity, and therefore, an interruption of the inflammatory cascade 
evident by the reduction of the levels of tissue eosinophils and peripheral blood, as well as of the 
GM-CSF, and IL-2, -4, and -13. They also decrease the presentation of allergens to T cells and the 
production of cytokines that stimulate differentiation toward the Th2 phenotype [19] (Figure 3).
The efficacy and safety of omalizumab treatment in severe asthma has been demonstrated 
in several controlled studies, showing a significant reduction in exacerbations, a steroid-
sparing effect, and improvement in quality of life. The greatest benefit has been observed in 
patients with allergic asthma, particularly those of greater severity, who failed to respond 
to conventional treatment [20]. Since 2003, this continues to be its main indication, when it 
was approved by the Food and Drug Administration (FDA). In 2005, it was approved by the 
European Medicines Agency (EMA) as an additional therapy in adult patients and in children 
older than 6 years with persistent severe uncontrolled allergic asthma, with decreased lung 
function (FEV1 less than 80% of predicted), despite the chronic management with high doses 
of inhaled corticosteroids plus long-acting beta 2-agonists and with evidence of sensitization 
to at least one aeroallergen in the skin test or by determination of specific IgE in blood [21]. In 
Colombia, Invima has approved it since 2005 with the same indication.
4.1.4. Interleukins 4 and 13
IL-4 and -13 are considered the most important cytokines in allergic inflammation in the respira-
tory tract for a long time; they are essential for the differentiation of CD4+ lymphocytes toward the 
Th2 phenotype. In addition, they are the promoters of the Ig class switch toward the production 
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of IgE, of the differentiation of the B cells in plasma producing specific Ig E, and of the recruitment 
of eosinophils to the airway through the receptors for them that are expressed in them. They also 
stimulate mast cells and other pro-inflammatory cells. IL-13 favors the development of airway 
fibrosis and mucus hypersecretion, and in conjunction with IL-4, induces inflammation, remodel-
ing, and the proliferation of bronchial fibroblasts and smooth muscle cells [22].
4.1.5. Interleukin 5
It is produced mostly by Th2 cells, mast cells, basophils, and eosinophils. This cytosine mainly 
conditions the population of eosinophils, from their medullary differentiation to their matu-
ration, survival, and activation. It is a potent inhibitor of eosinophilic apoptosis [23].
4.2. Future targets
4.2.1. Interleukin 9
It is produced by Th2, Th9, basophil, eosinophil, and mast cells, and is thought to be also by 
neutrophils. This cytokine acts by binding to its IL-9R alpha receptor, generating an increase 
in the proliferation and attraction of mast cells. It plays a very important role in the differen-
tiation and activation of Th2 cells. Together with interleukins 4 and 13, it acts on the smooth 
muscle and the airway epithelium, contributing to bronchial hyperreactivity [23].
4.2.2. Granulocyte macrophage colony-stimulating factor
It is a growth factor involved in the differentiation and survival of eosinophils [23].
Figure 3. Molecular effects of omalizumab. This antibody binds to soluble immunoglobulin E (IgE), preventing its 
binding to the high-affinity receptor on the mast cell membrane. This generates a negative feedback that induces the 
internalization of this receptor and the blockade of the entire intracellular inflammatory cascade with the subsequent 
anti-inflammatory effects. FCƐRI: high-affinity receptor for IgE; Eøs: eosinophils; GM-CSF: colony-stimulating factor of 
granulocytes and monocytes.
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4.2.3. Thymic stromal lymphopoietin
It is an epithelial cytokine similar to IL-7, produced in response to a pro-inflammatory stimu-
lus. It acts by inducing the release of cytokines from the Th2 pattern. Patients with asthma 
have elevated levels of this cytokine in their airway, showing a correlation between the degree 
of elevation and the severity of the disease. In fact, several studies have shown that some 
polymorphisms in the locus for the TSLP gene have a protective effect for the development of 
asthma and bronchial hyperreactivity [24].
4.2.4. Prostaglandin D2 receptor (PTGDR)
It is a receptor located in Th2 cells, innate lymphoid type 2 cells (ILC2), and in eosinophils. 
Prostaglandin D2 is its natural ligand. PTGDR activation stimulates the synthesis of Th2 
cytokines.
4.2.5. Interleukin 25
It is produced by epithelial cells in response to different stimuli. Through the induction of 
GATA 3, it favors the differentiation toward Th2 and ILC2 cells. It has an essential role in 
inflammation of the airway and in the remodeling process [25].
Figure 4. Different monoclonal antibodies with their respective therapeutic targets within the inflammatory cascade 
of asthma. The neutralization of the different receptors and mediators blocks the intracellular cascade of kinases that 
amplify the inflammatory process. IL-4Rα: alpha receptor for interleukin 4; IL-13 Rɑ1: alpha 1 chain of the interleukin 13 
receptor; rIL-4: inactive recombinant interleukin 4; S-U: subunit.
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Antibody
(references)
Type Target Study 
phase
Clinic outcomes Inflammatory 
outcomes
Dose/route/interval
Benralizumab
[27–31]
Humanized IL-5Rα II–III - Reduction of 
exacerbations, and 
hospitalization
- Improvement of 
FEV1
- Improvement of 
the quality of life
- ↓ eosinophilia
- ↓ sputum 
eosinophils
- ↓ECP
20–100 mg SC/4–8 weeks
Mepolizumab
[32–35]
Humanized IL-5S II–III - Reduction of 
exacerbations
- Reduction of 
dose of oral 
corticosteroids
- Improvement of 
the ACT
- Improvement of 
FEV1
- ↓ eosinophilia
- ↓ sputum 
eosinophils
75 mg IV/month
100 mg SC/month
Reslizumab
[36, 37]
Humanized IL-5S III - Improvement of 
FEV1
- Improvement of 
the ACT
- Improvement of 
symptoms
- Reduction of 
exacerbations
- ↓ sputum 
eosinophils
3 mg/kg IV/month
Dupilumab
[38, 39]
Human IL-4Rα II–III - Reduction of 
exacerbations
- Improvement of 
FEV1
-Improvement of 
the quality of life
- ↓ FeNO
- ↓ total IgE
- ↓ eotaxin 1
200 mg SC/2 weeks
Pitrakinra
[40, 41]
rIL-4 IL-4Rα II - Reduction of 
exacerbations*
- Reduction of night 
awakenings*
- Reduction of 
activities limitation 
by asthma*
- Reduction of 
exacerbations 
in patients with 
eosinophilia
- Reduction of need 
for beta-2’s rescue
-FEV1 improvement
- ↓ FeNO 3–10 mg inhaled/12 h
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4.2.6. Interleukin 33
IL-33 origin and actions are very similar to IL-25. Its effect is even greater and more potent on 
innate lymphoid cells compared to IL-25. In addition, it activates mast cells and basophils and 
is a survival factor for eosinophils [26].
4.2.7. Tumoral necrosis factor (TNF-a)
It is produced by epithelial cells, Th1 and Th17 cells. TNF-a promotes the recruitment of 
eosinophils and neutrophils to the airway by dysregulation of adhesion molecules. It activates 
macrophages for the production of growth factors and GM-CSF [25].
4.2.8. Intervention in the Th2 pathway with monoclonal antibodies
The possible therapeutic interventions with monoclonal antibodies for the treatment of 
asthma are outlined in Figure 4. The characteristics of the main molecules and the current 
evidence available for each of them are detailed in Table 1 [27–45]. Other monoclonal antibod-
ies have fewer studies and possibly have a residual role in the treatment of asthma [46–50].
5. Conclusion(s)
A significant percentage of patients with severe asthma do not achieve control of the disease 
despite receiving adequate treatment. Current guidelines are outdated and will be even more 
Antibody
(references)
Type Target Study 
phase
Clinic outcomes Inflammatory 
outcomes
Dose/route/interval
Lebrikizumab
[42, 43]
Humanized IL-13 II–III - Reduction of 
exacerbations
- Improvement of 
FEV1
- ↓ periostin 125–250 mg SC/month
Tralokinumab
[44, 45]
Human IL-13 II–III - Reduction 
of bronchial 
hyperreactivity
- Reduction of need 
for beta-2’s rescue
- Improvement of 
FEV1
- ↓ eosinophilia 300 mg SC/2–4 weeks
*Defects associated with specific polymorphisms. Other monoclonal antibodies that have been studied: anti-TSLP [46]; 
enokisumab (anti IL-9) [47]; anti-GM-CSF [48]; anti IL-25 [49]; anti IL-33 [50].
rIL-4: inactive recombinant interleukin 4; IL-5Rα: alpha receptor for interleukin 5; IL-5S: soluble interleukin 5; IL-
4Rα: alpha receptor for interleukin 4; IL-13: interleukin 13; FEV1: forced expiratory volume in the first second; NS: 
not significant difference; ACT: asthma control test; ECP: eosinophilic cationic protein; FeNO: expired fraction of nitric 
oxide; IgE: immunoglobulin E; SC: subcutaneous route; IV: intravenous route.
Table 1. Main monoclonal antibodies that have been studied for the treatment of asthma [27–45].
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if biomarkers and specific molecular susceptible of an intervention are not included in future 
guideline versions.
For now, omalizumab, the only biological treatment available for the management of severe 
asthma, continues influencing future studies aiming to evaluate new molecules and possible 
newer targets in selected patients. Linking the characteristics of each patient’s disease, with 
the effects of a specific monoclonal antibody, will surely imply a much more effective and 
timely control of the disease.
The detailed approach of the phenotypic characteristics and their molecular basis should lead 
to a personalized treatment of great precision and effectiveness. A very promising new era in 
the treatment of asthma is approaching.
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